Circulating miR-542-3p as a Prognostic Marker for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Hepatocellular carcinoma (HCC) is a major global cause of cancer mortality with a poor prognosis.
• MicroRNAs are emerging as critical biomarkers for HCC prognosis and therapeutic response.
• Current therapeutic advancements have not significantly improved HCC patient outcomes.

Purpose of the Study:

• To systematically review and meta-analyze the association between circulating miR-542-3p levels and HCC progression.
• To evaluate the diagnostic potential of miR-542-3p for HCC prognosis and therapeutic evaluation.
• To explore the utility of miR-542-3p as a biomarker in HCC management.

Main Methods:

• Systematic review and meta-analysis of seven studies on HCC and miR-542-3p.
• Data extraction and quality assessment using the QUADAS-2 method.
• Human miRNA pattern analysis using miRBase and tissue atlas databases.

Main Results:

• miR-542-3p demonstrated significant diagnostic potential for HCC prognosis and therapeutic evaluation.
• Pooled sensitivity was 0.79 (95% CI, 0.75-0.83) and pooled specificity was 0.34 (95% CI, 0.29-0.40).
• The diagnostic odds ratio was 7.2, with an AUC of 0.806, indicating moderate diagnostic accuracy.

Conclusions:

• miR-542-3p shows considerable potential as a prognostic biomarker for hepatocellular carcinoma.
• Its expression on the X chromosome ensures applicability across both sexes for HCC diagnosis.
• Future research should investigate combining miR-542-3p with targeted therapies to enhance patient outcomes.